INTERVENTION TO REDUCE HBV, HCV AND HIV IN IDUS

描述：（申请人摘要） 到目前为止，还没有关于注射器交换的随机对照试验 地方 本研究既是疗效研究，也是可行性研究 两组随机临床试验的设计，其中当前和先前 注射毒品使用者被分配到：（a）能够使用注射器 （B）无法进行注射器更换， 鼓励使用法律的药房销售代替。 所有受试者均接受随访 每六个月更新一次，并通过风险行为收集信息 评估，关于针头使用的补充调查表， 采购，定位信息，尿检安非他明，可卡因 代谢物和吗啡，以及肝炎标志物的血清学检测 B病毒。 还将监测人体免疫缺陷病毒的标志物。 将有一个数据安全和监测委员会，负责监督 研究的进展，并将对伦理问题进行监督 参与了这项研究。

DESCRIPTION: (Applicant's Abstract) To date no randomized controlled trials of syringe exchange have taken place. This research is both an efficacy study and a feasibility study design of a two group randomized clinical trial in which current and former injection drug users are assigned to: (a) being able to use a syringe exchange, or (b) not having access to the syringe exchange and being encouraged to use legal pharmacy sales instead. All subjects are followed up every six months and information is collected with Risk Behavior Assessment, a supplementary questionnaire concerning needle use and procurement, locator information, urine testing for amphetamines, cocaine metabolites, and morphine, and serological testing for markers of Hepatitis B Virus. Markers of Human Immunodeficiency Virus will also be monitored. There will be a Data Safety and Monitoring Board who will be overseeing the progress of the research and will have oversight over the ethical issues involved in this research.